They have a whole new life. They can actually plan their future.
In the long arc of medicine's struggle against inherited suffering, five scientists have reached a milestone once thought unreachable: the moment when a faulty gene ceased to be a permanent verdict. Jean Bennett, Albert Maguire, Katherine High, Stuart Orkin, and Swee Lay Thein have been awarded the 2026 Breakthrough Prizes for developing gene therapies — Luxturna and CASGEVY — that restore sight to the hereditarily blind and functionally cure blood disorders that have defined entire lifetimes by pain and limitation. Their work, conducted across decades and validated through regulatory pathways they themselves had to invent, has transformed not only individual lives but the architecture of possibility for thousands of rare genetic diseases still awaiting their turn.
- Patients with inherited blindness faced total vision loss by early adulthood, while sickle cell and beta-thalassemia sufferers endured relentless pain crises and organ damage with no cure in sight — the human cost of these diseases was both severe and largely invisible to medicine.
- Developing these therapies meant building the regulatory and scientific infrastructure from scratch, with researchers designing FDA trial protocols that had never existed and relying on colonies of blind dogs to generate the preclinical evidence needed to move forward.
- Luxturna's results stunned clinicians — patients reported their treated eye flooding with light within days, and one participant halved their obstacle-course time within a year, even as Maguire had described their retinas as appearing clinically dead.
- CASGEVY, the first CRISPR therapy approved by the FDA, sidesteps the need for a bone marrow donor by editing a patient's own stem cells to reactivate fetal hemoglobin production — but the year-long process and a $2.2 million price tag in the US mean access remains a profound and unresolved challenge.
- The field these five scientists seeded has grown exponentially: over 140 retinal disease trials are now underway, and researchers are beginning to find rare genetic mutations hiding inside common chronic illnesses, suggesting gene therapy's reach may extend far beyond rare disease.
Five scientists have been awarded the 2026 Breakthrough Prizes for developing gene therapies that have turned two categories of incurable inherited disease into treatable conditions. Jean Bennett, Albert Maguire, and Katherine High created Luxturna, a treatment for Leber congenital amaurosis — a form of inherited blindness caused by mutations in the RPE65 gene that strips patients of their sight progressively through childhood, leaving most completely blind by early adulthood. Before their work, physicians had nothing to offer. The trio had to construct the entire clinical and regulatory framework for proving such a therapy could work, collaborating with the FDA on trial protocols that had no precedent and drawing on colonies of genetically blind dogs as their preclinical model.
The results in human trials were immediate and dramatic. Patients described their treated eye suddenly flooding with light within days of injection. One participant navigated a dimly lit obstacle course in roughly half the time after treatment that it had taken before. Even patients whose retinas appeared severely degenerated showed meaningful recovery. Luxturna became the first FDA-approved gene replacement therapy in 2017 and has since restored vision to patients including a young child in the UK.
The second prize honors Stuart Orkin and Swee Lay Thein for CASGEVY, the first CRISPR-based gene editing therapy to receive FDA approval, targeting sickle cell disease and beta-thalassemia. Sickle cell patients endure unpredictable, crushing pain crises as misshapen red blood cells obstruct circulation; beta-thalassemia patients require lifelong transfusions that cause iron to accumulate and damage vital organs. The only prior hope for a cure — a bone marrow transplant — depended on finding a compatible donor, a particular obstacle for patients of African ancestry whose diseases are most prevalent but whose representation in donor registries is lowest.
Thein identified BCL11A as the gene governing both conditions, and Orkin's research mapped how it controls the developmental switch from fetal to adult hemoglobin — the moment when symptoms begin. CASGEVY uses CRISPR to edit this gene in a patient's own harvested stem cells, reactivating fetal hemoglobin production to compensate for defective adult hemoglobin. The process takes up to a year and requires chemotherapy to prepare the bone marrow. For those who complete it, the transformation is life-altering. The treatment costs $2.2 million in the United States, and access remains a serious barrier.
Beyond the two therapies themselves, the laureates' most enduring contribution may be the blueprint they have laid down for the entire field. When Maguire began presenting on gene therapy, he was often alone at the podium; now entire journals and scientific societies are devoted to the discipline, and more than 140 retinal disease trials are underway. Researchers are beginning to discover that some patients diagnosed with common chronic conditions may carry rare genetic mutations amenable to gene therapy — suggesting the field's horizon extends well beyond rare disease into medicine at large.
Five scientists have won this year's Breakthrough Prizes—often called the Oscars of Science—for developing gene therapies that treat diseases once considered incurable. Their work represents a turning point in medicine: the moment when genetic disease stopped being a life sentence and became something that could be fixed.
Jean Bennett, Albert Maguire, and Katherine High developed a treatment for Leber congenital amaurosis, a form of inherited blindness that gradually destroys the light-detecting cells in the retina. Patients with this condition experience tunnel vision that worsens over time, night blindness, and involuntary eye movements. Severe vision loss typically begins in childhood, and by early adulthood, most patients are completely blind. Before this treatment existed, there was nothing doctors could offer except counseling about canes and guide dogs. Desperate patients sometimes turned to charlatans, seeking any possibility of help. The disease is caused by mutations in the RPE65 gene, which encodes a protein critical to how the retina processes light. Bennett, Maguire, and High's idea was straightforward in theory: replace the defective gene with a working copy, delivered inside a harmless virus and injected directly into the eye. In practice, they had to invent the entire pathway for proving such a treatment worked. No one had done this before. They worked with the FDA to design clinical trial protocols from scratch, using preclinical data gathered from an unexpected source: dogs bred by kennel clubs and breeders who had inherited forms of blindness. University of Pennsylvania researchers had collected these animals and bred colonies of them specifically for genetic study, creating a living library of the disease.
When human trials began, the results were startling. Patients reported improvements within days—sometimes within a week—describing how everything suddenly became bright in the treated eye. One participant who took about 100 seconds to navigate an obstacle course in a dimly lit room before treatment completed the same course in 49 seconds just one year after injection. Even adults whose disease had progressed significantly, whose retinas looked what Maguire called "dead," showed substantial improvements in vision. Some were elated. By the end of 2017, the treatment—called Luxturna—became the first gene replacement therapy approved by the FDA. It has since changed the lives of patients including a 6-year-old girl in the UK who recently underwent the procedure.
The second prize recognizes Stuart Orkin and Swee Lay Thein for developing a CRISPR-based gene editing therapy for sickle cell disease and beta-thalassemia, two blood disorders caused by mutations in the BCL11A gene. Patients with sickle cell disease suffer recurrent, severe pain crises so debilitating that some describe the experience as being like having cancer and undergoing treatment continuously without ever getting better. The crises occur because red blood cells become sickle-shaped instead of disc-shaped, getting trapped in blood vessels and disrupting circulation. Patients never know when the next crisis will strike. Beta-thalassemia patients produce too little hemoglobin and often require lifelong blood transfusions, which causes iron to accumulate in the heart, liver, and other organs, causing damage. The only previous hope for a cure was a bone marrow transplant, but finding a compatible donor is far from guaranteed—particularly for patients of African ancestry, among whom these diseases are disproportionately common and where donor registries remain underrepresented.
Thein identified BCL11A as the key driver of both diseases, and Orkin's research showed how this gene controls the "hemoglobin switch"—the normal developmental process where the body stops producing fetal hemoglobin and switches to adult hemoglobin around six months of age. In patients with these blood disorders, this switch signals the beginning of their symptoms. Using CRISPR, Thein and Orkin developed a way to edit the BCL11A gene with precision, targeting a specific location that has no function outside red blood cells, minimizing the risk of unintended side effects. The treatment, called CASGEVY, became the first CRISPR-based gene editing therapy approved by the FDA. Unlike Luxturna, which is injected once into the eye, CASGEVY is an ex-vivo treatment requiring patients to have stem cells harvested, edited in a laboratory, and then reinfused after undergoing chemotherapy to make room in the bone marrow for the edited cells. The entire process can take up to a year and requires significant medical support. The treatment doesn't cure the underlying genetic condition; instead, it flips the hemoglobin switch back to producing fetal hemoglobin, which compensates for the defective adult hemoglobin. For patients who can access it, the transformation is profound. Orkin describes what patients experience after treatment: "They have a whole new life. They can actually plan their future."
Both treatments carry substantial barriers to access. CASGEVY costs $2.2 million in the United States. The procedure itself is intensive and carries risks of infection and other complications. Yet for those patients who benefit, the cost may represent savings over a lifetime of managing symptoms. The work of these five scientists has done more than create two new treatments; it has established a blueprint for how gene therapies can be developed and approved, creating a pathway that other researchers are now following. When Maguire began his work, he was often the only person presenting on gene therapy at medical conferences. Now there are journals and scientific societies devoted exclusively to the field. More than 140 clinical trials for retinal disease alone are underway. The laureates see the field as still in its infancy. High points out that roughly 7,000 rare diseases exist, and about 6,000 are caused by genetic conditions. Emerging research suggests that some people diagnosed with common chronic diseases like inflammatory bowel disease may actually have rare genetic mutations that could be treated with gene therapy. The landscape of genetic disease treatment is being redrawn, one approval at a time.
Citas Notables
I can't tell you how many times and how many people said, 'It will never work.' Hearing that was great motivation. The concept makes so much sense – we needed to prove the naysayers wrong.— Albert Maguire, gene therapy researcher
What patients describe after they're treated and functionally cured is they have a whole new life. They can actually plan their future.— Stuart Orkin, gene therapy researcher
La Conversación del Hearth Otra perspectiva de la historia
When you started this work, did you believe it would actually work?
Honestly, no. I probably told myself it wouldn't work more than once. Everyone said it wouldn't work. But the concept made so much sense that we felt we had to prove the naysayers wrong.
What surprised you most when patients started receiving the treatment?
The speed. I expected improvements might take 30 days based on animal models. But patients were calling within a week saying everything was suddenly bright in the treated eye. I thought their eyes were just irritated from surgery at first. Then the testing confirmed it. It was hard to believe.
For the blood disorder treatment, you're using CRISPR to edit genes. How is that different from what the blindness team did?
They replaced a defective gene with a working copy. We're editing the gene itself—making a precise cut at a specific location to change how it functions. It's like the difference between replacing a broken part versus adjusting how the part works.
Why does precision matter so much here?
BCL11A has multiple functions. If you disrupt all of them, you could cause serious side effects. By editing only the specific region involved in the hemoglobin switch, we minimize risk elsewhere in the body.
What's the biggest obstacle now?
Access. The treatment costs $2.2 million. The procedure itself is grueling—patients need chemotherapy, cell harvesting, laboratory editing, reinfusion. It's not something every patient can tolerate or afford. We need more options, more drugs, more approaches.
Do you think gene therapy will become routine?
We're just getting started. There are 7,000 rare diseases, 6,000 caused by genetic mutations. Most haven't been touched yet. If we can identify people with rare genetic mutations hiding inside common diseases, gene therapy could transform how we treat chronic illness entirely.